Returning for the 3rd year, the ILD Summit will lean into the industry’s key challenges, explore pipeline opportunity development, and look towards the future for ILD therapeutic development from idiopathic pulmonary fibrosis pipelines. From illuminating predictors of progression to define and identify the progressive fibrosis phenotypes for patient stratification to evolving clinical trial design with novel secondary and exploratory endpoints beyond FVC. This is a fantastic point in 2023 for the lung fibrosis community to come together to meet at the intersection of pulmonology and rheumatology to advance therapeutic development for ILDs.
To know more visit: https://ter.li/wc2uto